Analysts Anticipate 10% Upside For ESGU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares ESG Aware MSCI USA ETF (ESGU) has an implied analyst target price of $144.68, indicating a potential upside of 10.29% from its current trading price of $131.18. Notable underlying holdings with significant upside include ONEOK Inc, CVS Health Corporation, and Targa Resources Corp.
Investor Considerations: Analysts' target prices may reflect optimism about future stock performance, but investors should conduct further research to determine if these targets are justified or overly optimistic based on recent developments in the companies and their industries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to fall
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 100.480
Low
91.00
Averages
96.71
High
105.00
Current: 100.480
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Corporation Rated Among High Yield Stocks
- Attractive Dividend Yield: CVS Health Corporation boasts an annual dividend yield of 2.65%, placing it among the 12 high-yield Fortune 500 stocks, which attracts institutional investors due to its stable cash flow and return potential.
- Price Target Increase: Mizuho raised CVS's price target from $110 to $115 while maintaining an 'Outperform' rating, indicating analysts' confidence in the company's future performance and suggesting over a 14% upside from current levels.
- Improved Policy Environment: Analysts note that the managed care industry is entering a 'more stable and predictable' policy backdrop, with reduced frequency and severity of policy-related surprises, allowing investors to focus on company fundamentals and earnings potential.
- Significant Dividend Growth: CVS has achieved a 56.5% increase in dividends over the past decade, further solidifying its position as a favored high-yield stock for institutional investors, despite some AI stocks potentially offering greater upside.
See More
Humana Stock Shows Signs of Overbought Risk
- Stock Performance Review: Humana's stock has more than doubled since the market bottomed during the U.S.-Iran war on March 30, yet it was identified as one of the overbought stocks in the S&P 500 by the end of the week, indicating potential downside risk.
- Market Volatility Analysis: Despite choppy trading in major U.S. indexes over the past five sessions, the S&P 500 managed to rise for the 10th time in 11 weeks, reflecting complex investor sentiment influenced by geopolitical developments and the SpaceX IPO.
- Healthcare Sector Resilience: UBS noted that the healthcare sector outperformed the S&P 500 on 85% of the days when the benchmark fell by 1% or more over the past year, demonstrating the sector's resilience amid market turbulence.
- Analyst Rating Adjustments: Bank of America raised its price target for J.M. Smucker to $132, implying about a 14% potential upside from Friday's close, reflecting optimistic market expectations for the company's future performance.
See More
CVS Health Leverages AI to Enhance Healthcare Services
- Potential of Real-Time Data Sharing: Aetna's COO Guerraz highlighted that real-time data sharing between insurers and providers could significantly reduce administrative burdens over the next few years, accelerating patient access to care and potentially transforming industry operations.
- Application of Conversational AI Assistant: CVS's conversational AI assistant, launched on Aetna's website and mobile app, proactively answers member questions and provides relevant information without the need for customer service calls, with an expectation that 75% of common inquiries will be resolved through AI, thereby enhancing service efficiency.
- Prospects of Personal AI Assistant: The Health100 platform, developed in collaboration with Google Cloud, will feature a persistent personal AI assistant that actively manages patient needs in real time by integrating insurance, pharmacy, and clinical data, aiming to help patients better manage their health and reduce out-of-pocket costs.
- Shift to Preventive Healthcare Services: This AI assistant will proactively identify health issues and provide recommendations, aiming to reduce the
See More
AM Best Affirms Aetna's Financial Strength Ratings
- Rating Affirmation: AM Best has affirmed the Financial Strength Rating of A (Excellent) and Long-Term Issuer Credit Ratings of 'a' (Excellent) for Aetna Life Insurance Company and its subsidiaries, reflecting strong balance sheet strength and operational performance, which is expected to bolster investor confidence.
- Capital Structure Changes: Historically, Aetna has paid substantial dividends to its parent, but in 2024, capital contributions from CVS Health to support business growth led to a reduction in dividends, with expectations to return to historical levels, thereby improving capital adequacy ratios.
- Growth in Health Insurance: In 2025, Aetna's net premium written growth was primarily driven by government programs, particularly due to the Inflation Reduction Act's impact on Medicare Part D, although membership declined due to repricing strategies, with overall profitability showing improvement.
- Reinsurance Arrangements: Aetna Health & Life Group maintains moderate reinsurance leverage, utilizing traditional reinsurance with highly rated carriers and a quota share agreement with Health Re, Inc., enhancing its risk management capabilities and ensuring financial stability.
See More
Managed Care Stocks Surge Led by UnitedHealth
- Market Recovery: After a 35% decline last year, UnitedHealth (UNH) has surged approximately 21% year-to-date, indicating a strong rebound in the managed care sector, particularly led by the Medicare Advantage market.
- Payment Rate Increase: The Centers for Medicare & Medicaid Services finalized a 3% payment hike for Medicare Advantage players for next year, reflecting an improving backdrop of care utilization that further fuels optimism in the industry.
- Analyst Rating Upgrade: Following Bank of America's upgrade of UnitedHealth from Neutral to Buy, the stock rose about 5% on Thursday, with analyst Kevin Fischbeck projecting a broader managed care rally if utilization trends continue to improve.
- Attractive Valuations: Despite the positive outlook, UnitedHealth's EV/EBITDA valuation is roughly in line with its five-year average, while CVS Health shows only a ~7% premium, suggesting that the sector still has room for further upside given the favorable setup.
See More
IWD ETF 52-Week Price Fluctuation Analysis
- Price Range Analysis: The IWD ETF has a 52-week low of $188.55 and a high of $241.35, with the latest trade at $239.16, indicating stability near its high point, which may attract investor interest in its price fluctuations.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess market trends and potential buying opportunities, thereby optimizing investment decisions.
- ETF Trading Mechanism: ETFs trade in 'units', meaning investors are buying and selling these units rather than traditional 'shares', allowing ETFs to flexibly respond to market demand and enhance liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights notable inflows (new units created) or outflows (old units destroyed), which impacts the underlying holdings of the ETF and subsequently affects the market performance of related stocks.
See More
CVS Health Corporation Rated Among High Yield Stocks
- Attractive Dividend Yield: CVS Health Corporation boasts an annual dividend yield of 2.65%, placing it among the 12 high-yield Fortune 500 stocks, which attracts institutional investors due to its stable cash flow and return potential.
- Price Target Increase: Mizuho raised CVS's price target from $110 to $115 while maintaining an 'Outperform' rating, indicating analysts' confidence in the company's future performance and suggesting over a 14% upside from current levels.
- Improved Policy Environment: Analysts note that the managed care industry is entering a 'more stable and predictable' policy backdrop, with reduced frequency and severity of policy-related surprises, allowing investors to focus on company fundamentals and earnings potential.
- Significant Dividend Growth: CVS has achieved a 56.5% increase in dividends over the past decade, further solidifying its position as a favored high-yield stock for institutional investors, despite some AI stocks potentially offering greater upside.
See More
Humana Stock Shows Signs of Overbought Risk
- Stock Performance Review: Humana's stock has more than doubled since the market bottomed during the U.S.-Iran war on March 30, yet it was identified as one of the overbought stocks in the S&P 500 by the end of the week, indicating potential downside risk.
- Market Volatility Analysis: Despite choppy trading in major U.S. indexes over the past five sessions, the S&P 500 managed to rise for the 10th time in 11 weeks, reflecting complex investor sentiment influenced by geopolitical developments and the SpaceX IPO.
- Healthcare Sector Resilience: UBS noted that the healthcare sector outperformed the S&P 500 on 85% of the days when the benchmark fell by 1% or more over the past year, demonstrating the sector's resilience amid market turbulence.
- Analyst Rating Adjustments: Bank of America raised its price target for J.M. Smucker to $132, implying about a 14% potential upside from Friday's close, reflecting optimistic market expectations for the company's future performance.
See More
CVS Health Leverages AI to Enhance Healthcare Services
- Potential of Real-Time Data Sharing: Aetna's COO Guerraz highlighted that real-time data sharing between insurers and providers could significantly reduce administrative burdens over the next few years, accelerating patient access to care and potentially transforming industry operations.
- Application of Conversational AI Assistant: CVS's conversational AI assistant, launched on Aetna's website and mobile app, proactively answers member questions and provides relevant information without the need for customer service calls, with an expectation that 75% of common inquiries will be resolved through AI, thereby enhancing service efficiency.
- Prospects of Personal AI Assistant: The Health100 platform, developed in collaboration with Google Cloud, will feature a persistent personal AI assistant that actively manages patient needs in real time by integrating insurance, pharmacy, and clinical data, aiming to help patients better manage their health and reduce out-of-pocket costs.
- Shift to Preventive Healthcare Services: This AI assistant will proactively identify health issues and provide recommendations, aiming to reduce the
See More
AM Best Affirms Aetna's Financial Strength Ratings
- Rating Affirmation: AM Best has affirmed the Financial Strength Rating of A (Excellent) and Long-Term Issuer Credit Ratings of 'a' (Excellent) for Aetna Life Insurance Company and its subsidiaries, reflecting strong balance sheet strength and operational performance, which is expected to bolster investor confidence.
- Capital Structure Changes: Historically, Aetna has paid substantial dividends to its parent, but in 2024, capital contributions from CVS Health to support business growth led to a reduction in dividends, with expectations to return to historical levels, thereby improving capital adequacy ratios.
- Growth in Health Insurance: In 2025, Aetna's net premium written growth was primarily driven by government programs, particularly due to the Inflation Reduction Act's impact on Medicare Part D, although membership declined due to repricing strategies, with overall profitability showing improvement.
- Reinsurance Arrangements: Aetna Health & Life Group maintains moderate reinsurance leverage, utilizing traditional reinsurance with highly rated carriers and a quota share agreement with Health Re, Inc., enhancing its risk management capabilities and ensuring financial stability.
See More
Managed Care Stocks Surge Led by UnitedHealth
- Market Recovery: After a 35% decline last year, UnitedHealth (UNH) has surged approximately 21% year-to-date, indicating a strong rebound in the managed care sector, particularly led by the Medicare Advantage market.
- Payment Rate Increase: The Centers for Medicare & Medicaid Services finalized a 3% payment hike for Medicare Advantage players for next year, reflecting an improving backdrop of care utilization that further fuels optimism in the industry.
- Analyst Rating Upgrade: Following Bank of America's upgrade of UnitedHealth from Neutral to Buy, the stock rose about 5% on Thursday, with analyst Kevin Fischbeck projecting a broader managed care rally if utilization trends continue to improve.
- Attractive Valuations: Despite the positive outlook, UnitedHealth's EV/EBITDA valuation is roughly in line with its five-year average, while CVS Health shows only a ~7% premium, suggesting that the sector still has room for further upside given the favorable setup.
See More
IWD ETF 52-Week Price Fluctuation Analysis
- Price Range Analysis: The IWD ETF has a 52-week low of $188.55 and a high of $241.35, with the latest trade at $239.16, indicating stability near its high point, which may attract investor interest in its price fluctuations.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess market trends and potential buying opportunities, thereby optimizing investment decisions.
- ETF Trading Mechanism: ETFs trade in 'units', meaning investors are buying and selling these units rather than traditional 'shares', allowing ETFs to flexibly respond to market demand and enhance liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights notable inflows (new units created) or outflows (old units destroyed), which impacts the underlying holdings of the ETF and subsequently affects the market performance of related stocks.
See More
